RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Essential Thrombocythaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Transient Coronary Thrombosis Mimicking Myopericarditis Revealing JAK2-Positive Essential Thrombocythemia.
Kosum Paisit et al., JACC. Case reports (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42554550/
- 2.
Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia
Lucia Masárová et al., UNC Libraries (13 October 2026)
https://doi.org/10.17615/cj9n-1714
- 3.
Marrow hypercellularity is common and clinically neutral in essential thrombocythemia.
Erdos Katie et al., Leukemia (12 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42864415/
- 4.
Beyond IIH: Chronic CVST as the First Clue to Essential Thrombocythaemia
Shamera Hossain et al. (8 October 2026)
https://doi.org/10.13140/rg.2.2.26591.21929
- 5.
Impact of Metformin on the Incidence of Thrombosis in Older Adults with Polycythemia Vera or Essential Thrombocythemia and Diabetes.
Stempel Jessica M et al., Blood advances (6 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42837664/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727 · Recruiting · Phase 3 · Novartis Pharmaceuticals
Ages 18 and over
https://clinicaltrials.gov/study/NCT07357727
- 2.
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891 · Recruiting · Phase 1 · Prelude Therapeutics Incorporated
Ages 18 and over
https://clinicaltrials.gov/study/NCT07469891
- 3.
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
NCT07612280 · Recruiting · Phase 1 / Phase 2 · Jubilant Therapeutics Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07612280
- 4.
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631 · Recruiting · Phase 3 · Merck Sharp & Dohme LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT06351631
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Essential Thrombocythaemia
Essential Thrombocythaemia is the most common myeloproliferative neoplasm, characterised by sustained elevation of platelet count due to clonal bone marrow proliferation. It carries risks of thrombosis and bleeding, and a small proportion of patients transform to myelofibrosis or acute leukaemia. Management is risk-stratified and may include aspirin and cytoreductive therapy.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Acute coronary thrombosis without atherosclerosis may mimic myopericarditis, particularly in young patients. CASE SUMMARY: A 20-year-old woman presented with pleuritic chest pain following a viral illness. Serial electrocardiography showed dynamic ST-segment elevation in leads V3 to V6, and high-sensitivity troponin T increased from 18.6 to 1,151 ng/L. Echocardiography demonstrated regional wall motion abnormalities in the left anterior descending territory. Coronary angiography revealed a proximal left anterior descending intraluminal thrombus causing severe narrowing without underlying atherosclerosis. Conservative management with anticoagulation and dual antiplatelet therapy was initiated. Repeat angiography after 3 days showed complete thrombus resolution with no residual stenosis. Further evaluation revealed marked thrombocytosis and a JAK2 V617F mutation, confirming essential thrombocythemia. DISCUSSION: This case highlights a mechanism-based approach to myopericarditis-like presentations. JAK2-positive essential thrombocythemia represents a plausible prothrombotic contributor after the exclusion of common causes of coronary artery disease in very young patients. TAKE-HOME MESSAGE: Dynamic regional electrocardiogram changes, rapid troponin elevation, and regional wall motion abnormalities should prompt coronary evaluation despite pleuritic symptoms.
Common Questions
What is Essential Thrombocythaemia?
Essential Thrombocythaemia is the most common myeloproliferative neoplasm, characterised by sustained elevation of platelet count due to clonal bone marrow proliferation. It carries risks of thrombosis and bleeding, and a small proportion of patients transform to myelofibrosis or acute leukaemia. Management is risk-stratified and may include aspirin and cytoreductive therapy.
How many clinical trials are available for Essential Thrombocythaemia?
RareWays currently indexes 137 clinical trials for Essential Thrombocythaemia, of which 24 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Essential Thrombocythaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Essential Thrombocythaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.